Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.
04 Gennaio 2023 - 2:30PM
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), Dr. David Young,
Processa Pharmaceuticals, CEO will present an update on Processa’s
future therapeutic focus and strategy at the upcoming Biotech
Showcase on January 11, 2023, at 10 am. This presentation will also
be accessible at
https://event.webcasts.com/starthere.jsp?ei=1591773&tp_key=fbb2da9fa8
Processa management is available for one-on-one
meetings with potential investors and partners in San Francisco
throughout the J.P. Morgan 41st Annual HealthCare Conference week.
Meetings can be requested through the Biotech Showcase
partnering platform or by contacting Processa directly
at mfloyd@processapharmaceuticals.com
Details of Processa’s presentation at the
Biotech Showcase are as follows:
Date: Wednesday, January 11,
2023
Time: 10:00 AM
Track: Yosemite A (Ballroom
Level)
About Processa Pharmaceuticals,
Inc.
The mission of Processa is to develop products
with existing clinical evidence of efficacy for patients with unmet
or underserved medical conditions who need treatment options that
improve survival and/or quality of life. The Company uses its
Regulatory Science Approach criteria when selecting and developing
drugs to achieve high-value milestones effectively and efficiently.
Current clinical pipeline programs include: Next Generation
Capecitabine PCS6422 (metastatic colorectal cancer, breast cancer),
PCS3117 (pancreatic and other cancers), PCS11T (small cell lung and
other cancers), PCS12852 (gastroparesis, functional constipation),
and PCS499 (ulcerative necrobiosis lipoidica). Members of the
Processa development team have been involved with more than 30
approvals for indications in almost every division of the FDA
(including drug products targeted to orphan disease conditions) and
more than 100 FDA meetings throughout their careers. For more
information, visit our website at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking
statements. The statements in this press release that are not
purely historical are forward-looking statements which involve
risks and uncertainties. Actual future performance outcomes and
results may differ materially from those expressed in
forward-looking statements. Please refer to the documents filed by
Processa Pharmaceuticals with the SEC, specifically the most recent
reports on Forms 10-K and 10-Q, which identify important risk
factors which could cause actual results to differ from those
contained in the forward-looking statements.
For More Information:Michael Floyd(301)
651-4256mfloyd@processapharma.com
Patrick Lin(925) 683-3218plin@processapharma.com
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Lug 2023 a Lug 2024